Heart failure with preserved ejection fraction.

By Ali Ahmed, J. Fleg, M. Gheorghiade. New England Journal of Medicine, 2006

901 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Machine Learning in Medicine (2015, background): “Heart failure with preserved ejection fraction (HFpEF) is a highly heterogeneous condition with no proven therapies.(29)”
Myocardial Stiffness in Patients with Heart Failure and a Preserved Ejection Fraction: Contributions of Collagen and Titin (2015, result): “Additionally our data and the data of other investigators suggest that these sites on titin are also a target of CaMKII.(54,61,62) In both the current and previous studies in HFpEF patients,(28) hypophosphorylation of the N2B element has been observed.”
Heart failure: preventing disease and death worldwide (2014, background): “However, even the latest therapies may only relieve symptoms in many patients, without slowing the progression of their disease or prolonging life.(33,34) This is because heart failure can arise from a number of different underlying problems with the structure or function of the heart, some of which”
PHENOTYPE-SPECIFIC TREATMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTION: A MULTIORGAN ROADMAP (2016, background): “22 Collagen metabolism requires sequential, highly orchestrated and regulated steps: (1) procollagen synthesis and secretion, (2) procollagen postsynthetic processing, (3) collagen posttranslational modification, and (4) collagen degradation.”